Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus
| Autor: | Anthony L. Fine, Bryan C. Cannon, Kerry E Schueler, Michael E. Nemergut, Kara A. Bjur, Matthew J. Ritter |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Pentobarbital
business.industry Critically ill lcsh:RJ1-570 Lorazepam Case Report lcsh:Pediatrics General Medicine Status epilepticus 03 medical and health sciences 0302 clinical medicine Refractory Anesthesia Toxicity medicine Phenobarbital 030212 general & internal medicine Dosing medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Case Reports in Pediatrics, Vol 2017 (2017) Case Reports in Pediatrics |
| ISSN: | 2090-6811 2090-6803 |
| Popis: | Propylene glycol (PG) is a solvent commonly used in medications that, while benign at low doses, may cause toxicity in adults and children at high doses. We describe a case and the physiologic sequelae of propylene glycol toxicity manifested in a critically ill adolescent male with refractory myoclonic status epilepticus aggressively treated with multiple PG-containing medications (lorazepam, phenobarbital, and pentobarbital)—all within accepted dosing guidelines and a total daily PG exposure previously recognized to be safe. Hemodynamic measurements by bedside echocardiography during clinical toxicity are also reported. Clinicians should have a high index of suspicion for propylene glycol toxicity in patients treated with PG-containing medications even when the total PG exposure is lower than currently accepted limits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text